Comparison of two different Estrogen doses in prevention of synechia after hysteroscopic treatment of Asherman syndrom patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20141230020486N3

Enrollment

Registered

2018-02-04

Start date

2017-06-22

Completion date

Unknown

Last updated

2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asherman syndrome. Intrauterine synechiae

Interventions

Intervention 1: Control group: after surgery, patients receives Estrogen with 2.5 milligram dose daily for 40 days. In the last 10 days,10 milligram of Medroxyprogestron will also be daily prescribed

Eligibility

Sex/Gender

Female

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: all symptomatic patients (infertility or cyclic pelvic pain) referring to gynecology clinic of Imam Reza Hospital who are diagnosed with moderate to severe Asherman syndrome.

Exclusion criteria

Exclusion criteria: Another pathology in pelvic exam History of Uterine myoma or gynecology cancer hormone consumption during past month History of genital tuberculosis contraindication for hormone therapy

Design outcomes

Primary

Measure	Time frame
Percentage of people who face recurrence of synechia after treatment of Asherman syndrom. Timepoint: 2 months after using of estrogen. Method of measurement: After treatment period and and bleeding are over, all patients will again go through hysteroscopy and uterine cavity condition will be investigated.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Leili Hafizi

Mashhad University of Medical Sciences

hafizil@mums.ac.ir+98 51 3802 2608

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026